Two-year crizotinib monotherapy induced durable complete response of pediatric ALK-positive inflammatory myofibroblastic tumor

Pediatr Blood Cancer. 2023 Aug;70(8):e30330. doi: 10.1002/pbc.30330. Epub 2023 Apr 5.

Authors

Affiliations

¹ Department of Pediatrics, Tohoku University School of Medicine, Sendai, Japan.
² Department of Human Pathology, Juntendo University School of Medicine, Bunkyo, Tokyo, Japan.
³ Department of Medical Oncology, Juntendo University School of Medicine, Bunkyo, Tokyo, Japan.
⁴ Department of Medicine for Orthopaedics and Motor Organ, Juntendo University School of Medicine, Bunkyo, Tokyo, Japan.

PMID: 37017194
DOI: 10.1002/pbc.30330

No abstract available

Keywords: ALK; crizotinib; inflammatory myofibroblastic tumor.

Publication types

Letter

MeSH terms

Anaplastic Lymphoma Kinase / genetics
Child
Crizotinib / therapeutic use
Humans
Neoplasms*
Protein Kinase Inhibitors* / therapeutic use

Substances

Crizotinib
Protein Kinase Inhibitors
Anaplastic Lymphoma Kinase

Grants and funding